IQVIA (NYSE:IQV) Price Target Lowered to $200.00 at Citigroup

IQVIA (NYSE:IQV) had its price objective decreased by Citigroup from $230.00 to $200.00 in a research note issued on Friday,Benzinga reports. The brokerage presently has a “neutral” rating on the medical research company’s stock. Citigroup’s target price suggests a potential upside of 6.87% from the company’s current price.

IQV has been the topic of several other reports. Robert W. Baird set a $258.00 target price on shares of IQVIA and gave the stock an “outperform” rating in a research report on Wednesday, October 29th. Weiss Ratings reissued a “hold (c)” rating on shares of IQVIA in a research note on Thursday, January 22nd. Wall Street Zen upgraded IQVIA from a “hold” rating to a “buy” rating in a report on Sunday, January 25th. JPMorgan Chase & Co. boosted their price target on IQVIA from $177.00 to $255.00 and gave the company an “overweight” rating in a research report on Wednesday, October 29th. Finally, Barclays reduced their price objective on IQVIA from $230.00 to $210.00 and set an “equal weight” rating on the stock in a research note on Friday. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $243.63.

IQVIA Trading Up 3.4%

Shares of IQVIA stock traded up $6.19 during mid-day trading on Friday, hitting $187.15. 2,332,017 shares of the stock were exchanged, compared to its average volume of 1,633,401. IQVIA has a twelve month low of $134.65 and a twelve month high of $247.04. The company has a 50-day simple moving average of $228.83 and a 200 day simple moving average of $209.42. The stock has a market capitalization of $31.87 billion, a price-to-earnings ratio of 25.64, a price-to-earnings-growth ratio of 2.06 and a beta of 1.37. The company has a current ratio of 0.70, a quick ratio of 0.70 and a debt-to-equity ratio of 2.03.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Thursday, February 5th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.40 by $0.02. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.The business had revenue of $4.36 billion for the quarter, compared to analysts’ expectations of $4.24 billion. During the same quarter last year, the firm earned $3.12 earnings per share. The business’s revenue was up 10.3% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. Research analysts forecast that IQVIA will post 10.84 EPS for the current year.

Hedge Funds Weigh In On IQVIA

A number of hedge funds have recently bought and sold shares of IQV. Verdence Capital Advisors LLC acquired a new stake in shares of IQVIA during the second quarter worth $3,612,000. Amundi boosted its holdings in IQVIA by 46.3% in the 2nd quarter. Amundi now owns 1,279,817 shares of the medical research company’s stock valued at $210,722,000 after purchasing an additional 405,250 shares during the period. Diversified Trust Co grew its position in shares of IQVIA by 57.2% during the 3rd quarter. Diversified Trust Co now owns 42,579 shares of the medical research company’s stock worth $8,087,000 after purchasing an additional 15,487 shares in the last quarter. Nichols & Pratt Advisers LLP MA increased its holdings in shares of IQVIA by 8.6% during the third quarter. Nichols & Pratt Advisers LLP MA now owns 122,603 shares of the medical research company’s stock worth $23,287,000 after purchasing an additional 9,684 shares during the period. Finally, Act Two Investors LLC acquired a new stake in shares of IQVIA in the second quarter valued at approximately $26,528,000. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Key IQVIA News

Here are the key news stories impacting IQVIA this week:

• Positive Sentiment: Q4 results beat expectations — EPS $3.42 vs. ~$3.40 consensus and revenue $4.36B vs. ~$4.24B; revenue grew double digits year‑over‑year, supporting demand recovery from pharma clients. IQVIA Q4 Earnings & Revenues Beat Estimates
• Positive Sentiment: Company issued FY‑2026 guidance (EPS 12.55–12.85; revenue $17.2B–$17.4B) that is near or modestly above consensus revenue, giving a baseline for 2026 recovery expectations. IQVIA FY2026 Guidance (press materials)
• Neutral Sentiment: Analyst research/forecast pages provide varying takes on valuation and forward estimates — useful for modeling revisions but not a single consensus driver. IQVIA Stock Forecasts (Yahoo)
• Negative Sentiment: Market reaction and some coverage flagged the FY outlook as disappointing after accounting for higher interest expense — Reuters and others note annual profit forecasts were lowered, which dented sentiment and prompted price weakness in some sessions. IQVIA forecasts weak annual profit on higher interest expenses
• Negative Sentiment: Several outlets reported that the 2026 outlook missed portions of Wall Street expectations for adjusted earnings, triggering intraday selling and negative headlines. IQVIA Stock Drops as 2026 Outlook Misses
• Negative Sentiment: Analysts questioned the near‑term payoff from IQVIA’s AI strategy and at least one firm (BTIG) cut its rating to neutral, adding to downside pressure. IQVIA backs AI strategy as analysts question impact BTIG cuts IQVIA rating to neutral

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.